Akalu Temesgen Yihunie, Clements Archie C A, Wolde Haileab Fekadu, Alene Kefyalew Addis
School of Population Health, Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia.
Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Perth, Western Australia, Australia.
EClinicalMedicine. 2023 Mar 10;57:101900. doi: 10.1016/j.eclinm.2023.101900. eCollection 2023 Mar.
Physical sequelae related to multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are emerging and under-recognised global challenges. This systematic review and meta-analysis aimed to quantify the prevalence and the types of long-term physical sequelae associated with patients treated for MDR- and XDR-TB.
We systematically searched CINAHL (EBSCO), MEDLINE (via Ovid), Embase, Scopus, and Web of Science from inception through to July 1, 2022, and the last search was updated to January 23, 2023. We included studies reporting physical sequelae associated with all forms of drug-resistant TB, including rifampicin-resistant TB (RR-TB), MDR-TB, Pre-XDR-TB, and XDR-TB. The primary outcome of interest was long-term physical sequelae. Meta-analysis was conducted using a random-effect model to estimate the pooled proportion of physical sequelae. The sources of heterogeneity were explored through meta-regression using study characteristics as covariates. The research protocol was registered in PROSPERO (CRD42021250909).
From 3047 unique publications identified, 66 studies consisting of 37,380 patients conducted in 30 different countries were included in the meta-analysis. The overall pooled estimate was 44.4% (95% Confidence Interval (CI): 36.7-52.1) for respiratory sequelae, 26.7% (95% CI: 23.85-29.7) for hearing sequelae, 10.1% (95% CI: 7.0-13.2) for musculoskeletal sequelae, 8.4% (95% CI: 6.5-10.3) for neurological sequelae, 8.1% (95% CI: 6.3-10.0) for renal sequelae, 7.3% (95% CI: 5.1-9.4) for hepatic sequelae, and 4.5% (95% CI: 2.7-6.3) for visual sequelae. There was substantial heterogeneity in the estimates. The stratified analysis showed that the pooled prevalence of hearing sequelae was 26.6% (95% CI: 12.3-40.9), neurological sequelae was 31.5% (95% CI: 5.5-57.5), and musculoskeletal sequelae were 21.5% (95% CI: 9.9-33.1) for patients with XDR-TB, which were higher than the pooled prevalence of sequelae among patients with MDR-TB. Respiratory sequelae were the highest in low-income countries (59.3%) and after completion of MDR-TB treatment (57.7%).
This systematic review found that long-term physical sequelae such as respiratory, hearing, musculoskeletal, neurological, renal, hepatic, and visual sequelae were common among survivors of MDR- and XDR-TB. There was a significant difference in the prevalence of sequelae between patients with MDR- and XDR-TB. Post-MDR- and XDR-TB treatment surveillance for adverse outcomes needs to be incorporated into the current programmatic management of MDR-TB to enable early detection and prevention of post-treatment sequelae.
Australian National Health and Medical Research Council, through an Emerging Leadership Investigator grant, and the Curtin University Higher Degree Research scholarship.
与耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)相关的身体后遗症是新出现且未得到充分认识的全球性挑战。本系统评价和荟萃分析旨在量化与接受MDR-TB和XDR-TB治疗患者相关的长期身体后遗症的患病率及类型。
我们系统检索了CINAHL(EBSCO)、MEDLINE(通过Ovid)、Embase、Scopus和Web of Science,检索时间从数据库建库至2022年7月1日,最后一次检索更新至2023年1月23日。我们纳入了报告与各种形式耐药结核病相关身体后遗症的研究,包括耐利福平结核病(RR-TB)、MDR-TB、准广泛耐药结核病(Pre-XDR-TB)和XDR-TB。感兴趣的主要结局是长期身体后遗症。采用随机效应模型进行荟萃分析,以估计身体后遗症的合并比例。通过以研究特征作为协变量的荟萃回归来探索异质性来源。该研究方案已在国际前瞻性系统评价注册库(PROSPERO)注册(注册号:CRD42021250909)。
在识别出的3047篇独特文献中,纳入荟萃分析的有来自30个不同国家的66项研究,共37380例患者。呼吸后遗症的总体合并估计值为44.4%(95%置信区间(CI):36.7 - 52.1),听力后遗症为26.7%(95%CI:23.85 - 29.7),肌肉骨骼后遗症为10.1%(95%CI:7.0 - 13.2),神经后遗症为8.4%(95%CI:6.5 - 10.3),肾脏后遗症为8.1%(95%CI:6.3 - 10.0),肝脏后遗症为7.3%(95%CI:5.1 - 9.4),视觉后遗症为4.5%(95%CI:2.7 - 6.3)。各估计值存在显著异质性。分层分析显示,XDR-TB患者的听力后遗症合并患病率为26.6%(95%CI:12.3 - 40.9),神经后遗症为31.5%(95%CI:5.5 - 57.5),肌肉骨骼后遗症为21.5%(95%CI:9.9 - 33.1),均高于MDR-TB患者后遗症的合并患病率。低收入国家的呼吸后遗症患病率最高(59.3%),且在MDR-TB治疗结束后(57.7%)。
本系统评价发现,呼吸、听力、肌肉骨骼、神经、肾脏、肝脏和视觉等长期身体后遗症在MDR-TB和XDR-TB幸存者中很常见。MDR-TB和XDR-TB患者后遗症的患病率存在显著差异。MDR-TB和XDR-TB治疗后的不良结局监测需要纳入当前的MDR-TB规划管理中,以便早期发现和预防治疗后后遗症。
澳大利亚国家卫生与医学研究委员会,通过新兴领导力研究者资助项目,以及科廷大学高等学位研究奖学金。